• Behavioral Health
  • Clinical Insights
  • Treatment

August 2023 drug trend report

Aug 2nd, 2023

Genoa Healthcare’s latest drug trend report highlights information on new medication launches as well as noteworthy drug shortages currently in market.

Brand name drug launches*

Uzedy

  • Indicated for: Treatment of schizophrenia in adults.
  • Dosage form: Extended-release injectable suspension.
  • Status: Available now.

Abilify Asimtuffii

  • Indicated for: Treatment of schizophrenia in adults and as a maintenance monotherapy treatment of bipolar I disorder in adults.
  • Dosage form: Long-acting injectable.
  • Status: Available now.

Brixadi

  • Indicated for: Treatment of moderate to severe opioid use disorder in patients who have initiated treatment with a single dose of a transmucosal buprenorphine product or who are already being treated with buprenorphine.
  • Dosage form: Extended-release injectable.
  • Status: Expected September of 2023 (Genoa is working to become a REMS-certified pharmacy to dispense Brixadi).

Generic drug launches*

Vyvanse capsules and chewable tablets (Lisdexamfetamine Dimesylate)

  • Indicated for: Treatment of attention deficit hyperactivity disorder (ADHD) in adults and children 6 years of age and older.
  • Status: Expected August 25, 2023.

Current drug shortages*

Brand:

Adderall

  • Indicated for: Treatment of attention deficit hyperactivity disorder (ADHD) and/or narcolepsy.
  • Status: Estimated recovery December 2023.

Mounjaro

  • Indicated for: Decreases blood sugar (blood glucose) in adults with type 2 diabetes.
  • Status: Recovery TBD.

Ozempic

  • Indicated for: Decreases blood sugar (blood glucose) in adults with type 2 diabetes.
  • Status: Recovery TBD.

Generic:

Lorazepam

  • Indicated for: Treatment of anxiety and other indications.
  • Status: Estimated recovery August 2023

Clonazepam

  • Indicated for: Treatment of anxiety and other indications.
  • Status: Recovery TBD.

Divalproex DR 500mg

  • Indicated for: Treatment of bipolar disorder, migraines, and other indications.
  • Status: Recovery TBD.

*Information on this page was accurate at the time of posting. Shortage recovery dates are only estimates. These estimates are based on the distribution information that Genoa has access to.

Recent Posts


Partner with Genoa
  • Behavioral Health
  • Clinical Insights
  • Treatment
Brixadi®: 3 things to know about the buprenorphine treatment option

Staying on top of new medication therapy options for your consumers living with opioid use disorder (OUD) can be difficult. Learn how the new FDA-approved medication, Brixadi®, can help support...

  • People-first Pharmacy Care
Pharmacist Torquelia took a chance on herself to make a difference for others

If Torquelia Wynn, PharmD, sets her mind to something, it’s going to get done. The Thomasville, Georgia, Genoa Healthcare site manager grew up in Ashburn, Georgia – a small town...

  • Behavioral Health
  • Consumer Stories
  • People-first Pharmacy Care
Genoa Healthcare® Director of Operations featured in Chain Drug Review’s “Excellence in Pharmacy Practice” profile series

Alicia Garcia Afa, PharmD, RPh, a Genoa Healthcare director of pharmacy operations and previous pharmacist who recently helped a consumer navigate a mental health crisis, was featured in Chain Drug Review’s pharmacy...

  • People-first Pharmacy Care
Whether in his community or across the world, pharmacist Dylan strives to make an impact

It doesn’t feel like enough to say Dylan Bryant, PharmD, wears many hats. He’s a Genoa Healthcare pharmacist in Hays, Kansas, a husband and a dad to three kids ages...